Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus

Lea Duvnjak & Kristina Blaslov

SphygmoCor by the Numbers

Top 20

All “Top 20 Hospitals” use SphygmoCor technology to measure central blood pressure (cBP)

2,400+

SphygmoCor technology has supported studies that have resulted in over 2,400+ peer-reviewed publications.

8/10

8 out of top 10 Pharma companies have used SphygmoCor technology in their clinical trials

11,000

Over 11,000 patients have been tested with SphygmoCor technology in pharmaceutical trials

No results See all results